Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)

Summary

This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and potentially induce hair regrowth in patients with mild to moderate disease.

Timeline

Start

2018-11-15

Primary completion

2021-02-12

Completion

2021-02-12

Drugs

Indications